PA
MRNA icon

PSI Advisors’s Moderna MRNA Stock Holding History

PSI Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-55
Closed -$1.56K – 459
2025
Q1 		$1.56K Hold
55
– – ﹤0.01% 617
2024
Q4 		$2.29K Hold
55
– – ﹤0.01% 715
2024
Q3 		$3.68K Hold
55
– – ﹤0.01% 696
2024
Q2 		$6.53K Hold
55
– – ﹤0.01% 587
2024
Q1 		$5.86K Sell
55
-35
-39% -$3.53K ﹤0.01% 567
2023
Q4 		$8.95K Hold
90
– – ﹤0.01% 534
2023
Q3 		$9.3K Hold
90
– – ﹤0.01% 506
2023
Q2 		$10.9K Hold
90
– – ﹤0.01% 471
2023
Q1 		$13.8K Hold
90
– – 0.01% 391
2022
Q4 		$16.2K Sell
90
-25
-22% -$4.09K 0.01% 362
2022
Q3 		$14K Sell
115
-225
-66% -$34.1K 0.01% 377
2022
Q2 		$49K Buy
340
+4
+1% +$572 0.02% 255
2022
Q1 		$58K Sell
336
-102
-23% -$17.2K 0.02% 250
2021
Q4 		$111K Buy
438
+80
+22% +$23.4K 0.05% 191
2021
Q3 		$138K Buy
+358
New +$132K 0.06% 164

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

PSI Advisors's MRNA Position: Q2 2025 in Review

PSI Advisors sold out of Moderna (MRNA) in Q2 2025, closing a stake of 55 shares — an estimated $1.56K sold.

PSI Advisors first reported a position in MRNA in Q3 2021 and held it in 15 quarters. The position peaked at $138K in Q3 2021. 674 funds tracked by Wall St. Rank hold MRNA as of Q2 2025.

  • PSI Advisors reported no remaining Moderna position as of Q2 2025 after selling out during the quarter.
  • PSI Advisors sold 55 Moderna shares in Q2 2025, an estimated $1.56K.
  • PSI Advisors first reported a position in Moderna in Q3 2021 and held it in 15 quarters.
  • PSI Advisors's Moderna position peaked at $138K in Q3 2021.
  • 674 funds tracked by Wall St. Rank held Moderna as of Q2 2025.

Based on PSI Advisors's 13F filing for Q2 2025, filed 12 Aug 2025.